- Home
- SSTK vs MYGN Comparison
SSTK vs MYGN Comparison
Compare SSTK & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSTK
- MYGN
- Stock Information
- Founded
- SSTK 2003
- MYGN 1991
- Country
- SSTK United States
- MYGN United States
- Employees
- SSTK N/A
- MYGN N/A
- Industry
- SSTK EDP Services
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SSTK Technology
- MYGN Health Care
- Exchange
- SSTK Nasdaq
- MYGN Nasdaq
- Market Cap
- SSTK 1.1B
- MYGN 1.2B
- IPO Year
- SSTK 2012
- MYGN 1995
- Fundamental
- Price
- SSTK $25.38
- MYGN $14.18
- Analyst Decision
- SSTK Buy
- MYGN Hold
- Analyst Count
- SSTK 4
- MYGN 13
- Target Price
- SSTK $50.33
- MYGN $22.54
- AVG Volume (30 Days)
- SSTK 410.1K
- MYGN 1.2M
- Earning Date
- SSTK 02-25-2025
- MYGN 02-24-2025
- Dividend Yield
- SSTK 5.20%
- MYGN N/A
- EPS Growth
- SSTK N/A
- MYGN N/A
- EPS
- SSTK 1.01
- MYGN N/A
- Revenue
- SSTK $902,175,000.00
- MYGN $823,600,000.00
- Revenue This Year
- SSTK $9.51
- MYGN $13.60
- Revenue Next Year
- SSTK $12.56
- MYGN $3.25
- P/E Ratio
- SSTK $25.16
- MYGN N/A
- Revenue Growth
- SSTK 3.09
- MYGN 12.15
- 52 Week Low
- SSTK $25.13
- MYGN $12.04
- 52 Week High
- SSTK $54.41
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- SSTK 29.71
- MYGN 55.82
- Support Level
- SSTK $28.45
- MYGN $14.13
- Resistance Level
- SSTK $29.96
- MYGN $15.47
- Average True Range (ATR)
- SSTK 1.17
- MYGN 0.72
- MACD
- SSTK -0.45
- MYGN 0.27
- Stochastic Oscillator
- SSTK 3.57
- MYGN 61.38
About SSTK Shutterstock Inc.
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.